Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

So, it was a healthy start to the year, M&A-wise, for one of the worst-performing sectors of the S&P 500® in 2024. The Health ...

Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.

Donald Trump said the US would “take over” the Gaza Strip and that its 2.2mn inhabitants should be permanently resettled in countries such as Egypt and Jordan. “The US will take over the Gaza ...

CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has appointed Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer. The appointments are part of CTMC's ...

Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an ...